Preclinical models
Company-reported work shows reductions in NEC disease severity and affected gut regions. HPE has also shown increased weight gain in models of extreme prematurity.
ONE PLATFORM.
MULTIPLE POSSIBILITIES.
Protego-PD leads our work in regenerative biotherapeutics, beginning with premature infants.
Lead investigational candidate
PROTEGO-PD
A human placental extract candidate being developed for the prevention of necrotizing enterocolitis and to support immature digestive development.
Preclinical evidence · Clinical development preparation
FDA orphan drug and rare pediatric disease designations are development designations, not marketing approval.
Understand the platform
EVIDENCE FIRST.
PROGRESS WITH PURPOSE.
Clinical preparation
Plakous has described preparation for first-in-human clinical work. This is distinct from evidence of clinical efficacy or a confirmed recruiting trial.
Human evaluation
Clinical studies are needed to evaluate human safety and efficacy. Future milestones depend on study execution and regulatory review.
View the company’s published development timeline
Company-published planning timeline. Dates represent targets and must not be interpreted as completed milestones.
THE HORIZON
BEYOND NEC.
Potential future targets identified by Plakous. These are exploratory areas, not approved indications.
Pediatric malabsorption
Supporting immature digestive development is an initial research focus alongside NEC prevention.
Neurodevelopmental injury
Exploring the relationship between inflammation and brain development in premature infants.
Bronchopulmonary dysplasia
Investigating the potential of regenerative biotherapeutics for inflammation-associated lung injury.
Acute respiratory distress syndrome
A potential future focus on inflammation and injury in adult lungs.
Neurodegenerative diseases
Exploratory research into inflammatory mechanisms in Alzheimer’s disease, ALS and Parkinson’s disease.
Osteoarthritis
Company-reported preclinical work examines protection of joint cartilage.